Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G/A PAVmed Inc. Filed by: Tasso Partners, LLC

April 14, 2026 4:06 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: (1) Tasso Partners, LLC owns the shares of common stock of PAVmed Inc. (the "Issuer"); Tasso Capital, LLC is the manager which controls Tasso Partners, LLC and Dana Carrera controls Tasso Capital, LLC. (2) Consists of (i) 912,996 shares of common stock held by the Reporting Person and (ii) 5,365 warrants held by the Reporting Person exercisable for up to 5,365 shares of Series D Preferred Stock at an exercise price of $1,000 per share, each with a stated value of $1,000 and convertible at $6.50 per share into an aggregate of up to 825,385 shares of common stock (which the Issuer may issue directly upon exercise in lieu of the preferred shares), which contain a contractually stipulated 9.99% ownership restriction, which are beneficially owned by Dana Carrera, which is the trustee of GCL Family Trust (the "Trust"), and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended. (3) The percentage ownership was calculated based on a denominator which is the sum of 6,383,089 shares of common stock outstanding as of March 27, 2026, as set forth in the Issuer's annual report on Form 10-K filed on March 27, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: (1) Tasso Partners, LLC owns the shares of common stock the Issuer; Tasso Capital, LLC is the manager which controls Tasso Partners, LLC and Dana Carrera controls Tasso Capital, LLC. (2) Shared voting and dispositive power consist of (i) 912,996 shares of Common Stock held by Tasso Partners, LLC and (ii) 5,365 warrants held by Tasso Partners, LLC exercisable for up to 5,365 shares of Series D Preferred Stock at an exercise price of $1,000 per share, each with a stated value of $1,000 and convertible at $6.50 per share into an aggregate of up to 825,385 shares of common stock (which the Issuer may issue directly upon exercise in lieu of the preferred shares), which contain a contractually stipulated 9.99% ownership restriction, which are beneficially owned by Dana Carrera, which is the trustee of the Trust, and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended. (3) Sole voting and dispositive power consist of 61,250 shares of common stock owned by the Trust, which are beneficially owned by Dana Carrera, the trustee of the Trust. (4) Aggregate amount beneficially owned consists of (i) 912,996 shares of Common Stock held by Tasso Partners, LLC, and (ii) 61,250 shares of common stock owned by the Trust, which are beneficially owned by Dana Carrera, the trustee of the Trust, and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended. (5) The percentage ownership was calculated based on a denominator which is the sum of 6,383,089 shares of common stock outstanding as of March 27, 2026, as set forth in the Issuer's annual report on Form 10-K filed on March 27, 2026.


SCHEDULE 13G



Tasso Partners, LLC
Signature:/s/ Dana Carrera
Name/Title:Dana Carrera/Manager of Tasso Capital, LLC, which controls Tasso Partners, LLC
Date:04/14/2026
Dana Carrera
Signature:/s/ Dana Carrera
Name/Title:Dana Carrera
Date:04/14/2026

Categories

SEC Filings